Have you lost money investing in Eiger BioPharmaceuticals, Inc.? If yes, please visit us Eiger BioPharmaceuticals, Inc. Shareholder Class Action or contact Peter Allocco at (212) 951-2030 or [email protected] to discuss your rights.

NEW YORK, Nov. 15, 2022 (GLOBE NEWSWIRE) — Bernstein Liebhard LLP, a nationally recognized investor rights law firm, is reminding investors of the deadline for filing a motion by lead plaintiff in a securities class action lawsuit filed on behalf of investors who have purchased or acquired the securities of Eiger BioPharmaceuticals, Inc. (“Eiger” or the “Company”) (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, inclusive (the “Class Period”). The lawsuit was filed in the United States District Court for the Northern District of California alleging violations of the Securities Exchange Act of 1934.

Eiger is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases. The company’s product candidates include peginterferon lambda. Peginterferon Lambda is being evaluated for, Among other thingsthe treatment of COVID-19 in the TOGETHER Study to be an independent, multi-center, investigator-sponsored, randomized, placebo-controlled, adaptive-platform, Phase 3 study evaluating multiple therapeutics in newly diagnosed, out-of-hospital, high-risk patients with mild-to-moderate COVID-19 be rated. Added peginterferon lambda TOGETHER Studying in May 2021.

In March 2022, based on the results of the TOGETHER study, Eiger announced that it has received an Emergency Use Authorization (“EUA”) application from the U.S. Food and Drug Administration (“FDA”) for peginterferon lambda to treat patients with mild to moderate COVID-19 (the “peginterferon lambda EUA “).

Plaintiff alleges that throughout the Class Period, Defendants made materially false and misleading statements. Special,…